Common Contracts
2 similar Option and License Agreement contracts by Voyager Therapeutics, Inc.
OPTION AND LICENSE AGREEMENT By and between VOYAGER THERAPEUTICS, INC. AND NOVARTIS PHARMA, A.G. March 4, 2022Option and License Agreement • March 7th, 2023 • Voyager Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This OPTION AND LICENSE AGREEMENT (the “Agreement”) is entered into and made effective as of March 4, 2022(the “Effective Date”), by and between Voyager Therapeutics, Inc., a Delaware corporation, having its principal place of business at 75 Sidney Street, Cambridge, MA 02139 (“Voyager”), and Novartis Pharma AG, a corporation, having its principal place of business at Lichtstrasse 35, CH-4056 Basel, Switzerland (“Novartis”). Voyager and Novartis are referred to herein individually as a “Party” and collectively as the “Parties”.
OPTION AND LICENSE AGREEMENT By and between VOYAGER THERAPEUTICS, INC. AND NOVARTIS PHARMA, A.G.Option and License Agreement • May 4th, 2022 • Voyager Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This OPTION AND LICENSE AGREEMENT (the “Agreement”) is entered into and made effective as of March 4, 2022(the “Effective Date”), by and between Voyager Therapeutics, Inc., a Delaware corporation, having its principal place of business at 75 Sidney Street, Cambridge, MA 02139 (“Voyager”), and Novartis Pharma AG, a corporation, having its principal place of business at Lichtstrasse 35, CH-4056 Basel, Switzerland (“Novartis”). Voyager and Novartis are referred to herein individually as a “Party” and collectively as the “Parties”.
